A Study To Assess ZD6474 (ZACTIMA™) Monotherapy In Locally Advanced or Metastatic Hereditary Medullary Thyroid Cancer

• Status: Completed
• Trial end date: 2014-05-01
• Target enrollment: 0
• Participant gender: All

Summary

This will be a Phase II, open label study to establish the effect of once-daily oral doses of ZD6474 100mg in subjects with locally advanced or metastatic hereditary medullary thyroid cancer in whom no standard therapeutic option is available.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: AstraZeneca; Genzyme, a Sanofi Company

Criteria

Inclusion Criteria:

• Provision of written informed consent

• Previously confirmed histological diagnosis of locally advanced or metastatic hereditary medullary thyroid carcinoma without standard therapeutic options

• Aged 18 or over and a life expectancy of more than 12 weeks

Exclusion Criteria:

• The last dose of prior chemo/radiation received less than 4 weeks before the start of study therapy

• Congenital long QT syndrome or 1st degree relative with unexplained sudden death under 40 years of age, history of arrhythmia